Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Capital Leases (2017 - 2023)

Vistagen Therapeutics' Capital Leases history spans 8 years, with the latest figure at $6000.0 for Q4 2023.

  • For Q4 2023, Capital Leases changed N/A year-over-year to $6000.0; the TTM value through Dec 2023 reached $6000.0, changed N/A, while the annual FY2020 figure was $3000.0, N/A changed from the prior year.
  • Capital Leases for Q4 2023 was $6000.0 at Vistagen Therapeutics, down from $6500.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $7000.0 in Q2 2023 and bottomed at $300.0 in Q4 2020.
  • The 3-year median for Capital Leases is $4300.0 (2019), against an average of $4030.0.
  • The largest annual shift saw Capital Leases plummeted 36.05% in 2019 before it tumbled 92.31% in 2020.
  • A 3-year view of Capital Leases shows it stood at $3900.0 in 2019, then crashed by 92.31% to $300.0 in 2020, then soared by 1900.0% to $6000.0 in 2023.
  • Per Business Quant, the three most recent readings for VTGN's Capital Leases are $6000.0 (Q4 2023), $6500.0 (Q3 2023), and $7000.0 (Q2 2023).